AskenasyJJ. The functions and dysfunctions of laughter. J Gen Psychol1987;114:317–34.
2.
BlackDW. Pathological laughter. A review of the literature. J Nerv Ment Dis1982;170:67–71.
3.
LishmanAW. Organic psychiatry – the psychological consequences of cerebral disorder. 3rd ed.Malden (MA): Blackwell Science Ltd; 1998. p 19,96.
4.
RussellJDRoxanasMG. Psychiatry and the frontal lobes. Aust N Z J Psychiatry1990;24:113–32.
5.
Perugi G and others. Depressive comorbidity of panic, social phobic, and obsessive–compulsive disorders re-examined: Is there a bipolar II connection?J Psychiatr Res1999;33:53–61.
SoueryDAmsterdamJde MontignyCLecrubienYMontogemeryS, Lipp O, and others. Treatment resistant depression: Methodological overview and operational criteria. Eur Neuropsychopharmacol1999;9:83–91.
8.
O'ReardonJPAmsterdamJD. Treatment-resistant depression: Progress and limitations. Psychiatric Annals1998;28:633–40.
9.
Canadian Network for Mood and Anxiety Treatments (CANMAT). Guidelines for the diagnosis and pharmacological treatment of depression. Toronto: Cameron McCleery Productions Ltd; 1999.
10.
KesslerRCNelsonCBMcGonagleKALiuJSwartzMBlazerDG. Comorbidity of DSM-III-R major depressive disorder in the general population: Results from the US national comorbidity survey. Br J Psychiatry1999;30(168 Suppl):17–30.
11.
KaschKLKleinDN. The relationship between age at onset and comorbidity in psychiatric disorders. J Nerv Ment Dis1996;184:703–7.
12.
PiniSDell'OssoLMastrocinqueCMarcacciGPapasogliA, Vignoli S, and others. Axis I comorbidity in bipolar disorder with psychotic features. Br J Psychiatry1999;175:467–71.
13.
HimmelhochJM. The paradox of anxiety syndromes comorbid with the bipolar illnesses. In: GoldbergJFHarrowM, editors. Bipolar disorders. Clinical course and outcome. Washington (DC): American Psychiatric Press; 1999. p 237–58.
14.
AngstJ. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord1998;50:143–51.
15.
McMahonFJStineOCChaseGAMeyersDASimpsonSGDePauloR. Influence of clinical subtype, sex, and lineality on age at onset of major affective disorder in a family sample. Am J Psychiatry1994;151:210–5.
16.
BenazziF. Prevalence of bipolar II disorder in outpatient depression: A 203-case study in private practice. J Affect Disorder1997;43:163–6.
17.
BenazziF. Prevalence and clinical features of atypical depression in depressed outpatients: A 467-case study. Psychiatry Res1999;86:259–65.
18.
GoldbergJFKocsisJH. Depression in the course of bipolar disorder. In: GoldbergJFHarrowM, editors. Bipolar disorders. Clinical course and outcome. Washington (DC): American Psychiatric Press; 1999. p 129–47.
19.
AkiskalHS. The prevalent clinical spectrum of bipolar disorders: Beyond DSM-IV. J Clin Psychopharmacol1996;16(Suppl 1):4S–14S.
20.
FirstMBSpitzerRLGibbonMWilliamsJBW. Structured clinical interview for DSM-IV Axis I Disorders–Clinician Version (SCID-CV). Washington (DC): American Psychiatric Press; 1997.
21.
PerugiGToniCAkiskalHS. Anxious-bipolar comorbidity: Diagnostic and treatment challenges. In: AkiskalHS, editor. Bipolarity: Beyond classic mania. Psychiatr Clin North Am1999;22:565–83.
22.
RosensteinDLNelsonCJacobsSC. Seizures associated with antidepressants: A review. J Clin Psychiatry1993;54:289–99.
23.
GoldsteinLBarkerMSegallFAsiheneRBaiserS, Lautenbach D, and others. Seizure and transient SIADH associated with sertraline [letter]. Am J Psychiatry1996;153:732.
24.
BrittonJWSoEL. New Antiepileptic drugs: Prospects for the future. Journal of Epilepsy1995;8:267–81.
25.
CalabreseJRSheltonMDIIIKeckPEJrMcElroySLWerknerJE. Pilot study of topiramate in acute severe treatment-refractory mania [Abstract NR202], 151st Annual Meeting of the American Psychiatric Association; 1998 May 30 – June 4; Toronto. Washington (DC): American Psychiatric Association; 1998.
26.
HussainMZChaudhryZA. Treatment of bipolar disease with topiramate: A new anticonvulsant drug [Abstract NRP2b]. Book of abstracts. Canadian Psychiatric Association 48th Annual Meeting; 1998 Sept 15–18; Halifax, NS. Ottawa: Canadian Psychiatric Association; 1998. p 44.
27.
NatschSHeksterYAKeyserADeckersCLMeinardiHRenierWO. Newer anticonvulsant drugs: Role of pharmacology, drug interactions and adverse reactions in drug choice. Drug Safety1997;17:228–40.
28.
EngelskjonTJohannessenSKlosterRNakkenKLossiusRHeinriksenO. Long term effect of topiramate in refractory partial epilepsy. Epilepsy1993;34:305–11.
29.
PeruccaEBialerM. The clinical pharmacokinetics of the newer antiepileptic drugs: Focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet1996;31:29–46.
30.
JonesMW. Topiramate – safety and tolerability. Can J Neurol Sci1998;24:13S–15S.
31.
ShorvonSD. Safety of topiramate: Adverse events and relationships to dosing. Epilepsia1996;37(Suppl 2):S18–S22.
32.
Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry1999;156:1686–96.
33.
Weight gain associated with antipsychotic drugs. J Clin Psychiatry1999;60Suppl 21: 20–4.
34.
Novel antipsychotics: Comparison of weight gain liabilities. J Clin Psychiatry1999;60:358–63.
35.
GilligPSackellaresJCGreenbergHS. Right hemisphere partial complex seizures mania, hallucinations, and speech disturbances during ictal events. Epilepsia1988;29:26–9.
36.
DrakeMEJr., Episodic depression and hypomania with temporal EEG paroxysms. Psychosomatics1988;29:354–7.
37.
RoxanasMGCorbettAJReidGJ. A patient with mania and photoconvulsive epilepsy. Aust N Z J Psychiatry1996;30:867–70.
38.
WolfP. Manic episodes in epilepsy. In: AkimotoH, Kazamatsuri M, and others, editors. Advances in epileptology: XIIIth Epilepsy International Symposium. New York: Raven Press; 1982. p 237–40.
39.
BarczakPEdmundsEBettsT. Hypomania following complex partial seizures: A report of three cases. Br J Psychiatry1988;152:137–9.
40.
SavardGAndermannFOlivierARémillardGM. Postictal psychosis after complex seizures: A multiple case study. Epilepsia1991;32:225–31.
41.
Flor-HenryP. Schizophrenic-like reactions and affective psychoses associated with temporal lobe epilepsy: Etiological factors. Am J Psychiatry1969;126:400–4.